Judge Advises Freeing Amgen, Teva From Suits Over Sensipar

Law360 (July 24, 2020, 10:02 PM EDT) -- A Delaware federal judge has recommended the dismissal of two antitrust class actions against pharmaceutical giants Amgen and Teva Pharmaceuticals over their agreement to pull a generic version of a calcium control drug off the market, saying the lawsuits failed to properly allege the agreement included an unlawful "pay for delay" deal.

U.S. Magistrate Judge Jennifer L. Hall said in an opinion on Thursday that the direct and indirect purchasers of Sensipar, also known as cinacalcet, had failed to prove that Amgen Inc. and Teva Pharmaceuticals USA Inc.'s 2018 agreement included "large and unjustified" reverse payments, which is required in order...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!